Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 286

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 286
---
 are beyond our control, that could negatively affect the market price of our Common Stock or result in fluctuations
in the price or trading volume of our Common Stock, including:

    ●
    actual or anticipated
    variations in our annual or quarterly results of operations, including our earnings estimates and whether we meet market expectations
    with regard to our earnings;

    ●
    our current inability
    to pay dividends or other distributions;

56 

    ●
    publication of research
    reports by analysts or others about us or the industry in which we operate, including the pharmaceutical or biotechnology
    industry which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis;

    ●
    changes in market
    valuations of similar companies;

    ●
    market reaction
    to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings
    of our existing stockholders;

    ●
    additions or departures
    of key personnel;

    ●
    actions by institutional
    or significant stockholders;

    ●
    short interest in
    our Common Stock or our other securities and the market response to such short interest;

    ●
    the dramatic increase
    in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative
    investing;

    ●
    speculation in the
    press or investment community about our company or industries in which we operate;

    ●
    strategic actions
    by us or our competitors, such as acquisitions or other investments;

    ●
    legislative, administrative,
    regulatory or other actions affecting our business, our industry, including positions taken by the FDA;

    ●
    investigations,
    proceedings, or litigation that involve or affect us;

    ●
    the occurrence of
    any of the other risk factors included in this Report; and

    ●
    general market and
    economic conditions.

Our
Common Stock is currently listed on The NYSE American LLC (“NYSE American)”. NYSE American may delist our Common Stock
from trading, which could limit investors’ ability to make transactions in our securities and subject us to additional trading
restrictions.

Should
we fail to satisfy the continued listing requirements for remaining listed on NYSE American, such as the corporate governance
requirements or the minimum closing bid price requirement, NYSE American may take steps to delist our Common Stock. Such a delisting
would likely